M6P/IGF2R is mutated in squamous cell carcinoma of the lung.
about
Binding of urokinase-type plasminogen activator receptor (uPAR) to the mannose 6-phosphate/insulin-like growth factor II receptor: contrasting interactions of full-length and soluble forms of uPARDominant-negative effect of truncated mannose 6-phosphate/insulin-like growth factor II receptor species in cancerDecreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cellsDown-regulation of the M6P/IGF-II receptor increases cell proliferation and reduces apoptosis in neonatal rat cardiac myocytesM6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosisHigh throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancerStructure of a functional IGF2R fragment determined from the anomalous scattering of sulfur.Loss of heterozygosity on chromosome 6q correlates with decreased thrombospondin-2 expression in human salivary gland carcinomasMannose 6-phosphate receptors: new twists in the taleIdentification of cell surface and secreted proteins essential for tumor cell survival using a genetic suppressor element screen.Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer.IGF2R missense single-nucleotide polymorphisms and breast cancer risk: the multiethnic cohort study.R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axisIGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas.Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27Exploring the transcriptome space of a recombinant BHK cell line through next generation sequencing.Tissue-specific inactivation of murine M6P/IGF2R.Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.Cross-species clues of an epigenetic imprinting regulatory code for the IGF2R gene.Paternal and maternal genomes confer opposite effects on proliferation, cell-cycle length, senescence, and tumor formation.Structure and function of the human Gly1619Arg polymorphism of M6P/IGF2R domain 11 implicated in IGF2 dependent growthClinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma.Type I insulin-like growth factor receptor signaling in hematological malignancies.Very large common fragile site genes and their potential role in cancer development.Identification of residues essential for carbohydrate recognition by the insulin-like growth factor II/mannose 6-phosphate receptor.WWOX, large common fragile site genes, and cancer.Parkin and mitophagy in cancer.Effects of alpha-interferon on insulin-like growth factor-I, insulin-like growth factor-II and insulin-like growth factor binding protein-3 secretion by a human lung cancer cell line in vitro.Mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R) variants in American and Japanese populations.The mannose 6-phosphate/insulin-like growth factor II receptor restricts the tumourigenicity and invasiveness of squamous cell carcinoma cells.High expression of Parkin predicts easier recurrence of patients with adjuvant transarterial chemoembolization.Novel mutational landscapes and expression signatures of lung squamous cell carcinoma.The consequences of insulin-like growth factors/receptors dysfunction in lung cancer.Association between Gly1619ARG polymorphism of IGF2R domain 11 (rs629849) and advanced stage of oral cancer.
P2860
Q24298783-18132704-9157-4A49-8D37-0B490A9B8D40Q24337644-F231B61B-93D0-4563-B0DE-2D1BCDBD8E1CQ24798573-4D861158-189D-4CB3-81D6-9BFC5B3D36A6Q24798846-84D5A275-AB0B-492A-98E0-ADB11E45C7C7Q24805128-E5E5737A-B75B-44E0-B533-DE92F7C5C05EQ25257400-104D01EB-E250-49B6-8468-1F57267206CFQ27638084-C00E3FCF-F597-4413-A889-80D07F21BF2CQ28181944-BF31A808-0A89-400F-AFDE-9F91470FB8E5Q28213265-31B5F91F-3EE1-40EA-AF35-3D229CAB4B4EQ31111319-C6269A83-5F9B-4E47-AFB3-061A5830EF18Q33227693-813FA7A5-19E5-485A-9704-15565B4A1083Q33883948-32298818-D023-488D-9EC0-FEDCD9EB5C8CQ34055933-C536F95E-5216-4FD1-B4AE-43B4F373748BQ34434005-929A44F7-DC76-4DF1-A5C6-3FF9C324CD7AQ35022507-E5A78CB0-2419-4688-A16F-9ED0FAC36E06Q35046301-EE93EE6B-3DF7-4541-8902-2D100BE0C300Q35748838-6877FDDA-730F-43F2-A0B0-ECD89103D08DQ36185627-FE01402F-EA9E-47E5-A6F6-F784C7DE180CQ36436577-1D63CC79-8036-44A9-9B89-C60EC71AE5FCQ37089178-377AB607-82A2-4219-BAE0-FBD437FB7D4FQ37136974-7B7D26E1-E17A-41F4-A7BB-21E9CCD635F5Q37220672-14E1840C-76CE-4EDA-BE86-D1483E3B1118Q37702186-AE6D8121-4DF3-4339-ADA5-1D17FB157DBCQ38258543-23AD343A-3CB5-42C9-BD68-F591D8130F12Q38292872-4DBAB3A9-868E-4322-A496-33230A4A7A48Q38321093-9397CB57-916F-426A-A3A7-3E46A38B4BEDQ38946190-CFC5C878-8AA5-409D-89ED-4F6237C8F87DQ40390038-D55888D4-DC13-4C31-AFCC-5F32924A52FFQ43663105-5390E3F8-163A-4D84-A1DF-639F0C01EB46Q46132552-5B568EB8-AB4C-421F-8934-57EAA3A919CCQ50236833-C030EFBF-7EE9-4D5D-A888-F404DB50FD0DQ50320439-EC4164D8-7C36-4FC9-AC4E-7A0620C1726FQ52560904-0C01D3FE-9648-4CBA-A3C4-4943F650B6EBQ54386247-60B22D43-24ED-4528-A310-60B946E5A3E1
P2860
M6P/IGF2R is mutated in squamous cell carcinoma of the lung.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
M6P/IGF2R is mutated in squamous cell carcinoma of the lung.
@en
type
label
M6P/IGF2R is mutated in squamous cell carcinoma of the lung.
@en
prefLabel
M6P/IGF2R is mutated in squamous cell carcinoma of the lung.
@en
P2093
P2860
P356
P1433
P1476
M6P/IGF2R is mutated in squamous cell carcinoma of the lung.
@en
P2093
Anscher MS
Killian JK
Washington MK
P2860
P2888
P304
P356
10.1038/SJ.ONC.1203437
P407
P577
2000-03-01T00:00:00Z
P5875
P6179
1039064039